Burden of C. difficile Infection: Clinical Burden Explore 2.0

Posted on by microbiomestg

Clinical Burden

CLINICAL BURDEN OF C. DIFF INFECTION

A VICIOUS CYCLE OF RECURRENCE WITH A SIGNIFICANT BURDEN1,2

Significant complications associated with CDI

Recurrence

Recurrence:

Up to 35%3,4,a
Subsequent recurrence

Subsequent Recurrence:

Up to 60%5-9
Sepsis

Sepsis:

27%6
Colectomy

Colectomy:

7%10,b
Heart Failure

Heart Failure:

43%9
Mortality

Mortality:

6%3
Virus

Mortality in patients with COVID-19 and CDI: 44%8

Virus

Financial Burden

RECURRENT C. DIFF INFECTION BURDEN

RECURRENT CDI (RCDI) AFFECTS PATIENT QUALITY OF LIFE,
HOSPITAL QUALITY METRICS, AND REIMBURSEMENT

  • Patient in bed
    Up to 85% of all patients with rCDI were hospitalized in 12 months12
  • Patient
    57% of patients with at least one CDI recurrence experienced ≥2 admissions within 12 months9
  • Calendar
    Hospitalizations average 18 days for patients with rCDI9
  • Patient readmission
    84% of patients with rCDI are readmitted12
  • Dollar sign
    −$3K to −$29K gap exists in reimbursement per patient13
  • Hospital
    $131K to $207K comprised total cost of a patient with rCDI13

Physical/Psychological Burden

PHYSICAL/PSYCHOLOGICAL RECURRENT C. DIFF INFECTION BURDEN

THE PHYSICAL AND PSYCHOLOGICAL IMPACT OF RECURRENT CDI IS HIGH15

In an observational, cross-sectional study surveying 350 self-reported patients with CDI15

Person holding head

~41%

believed they would never get rid of post-CDI symptoms

Used with permission from Creative Commons. https://creativecommons.org/licenses/by/4.0/legalcode.15

aWithin 8 weeks after initial C. difficile infection diagnosis.
bFirst recurrence.

References: 1. Centers for Disease Control and Prevention. https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf. Accessed August 25, 2021. 2. Feuerstadt P, et al. J Med Econ. 2020;23(6):603-609. 3. Lessa FC, et al. N Engl J Med. 2015;372(9):825-834. 4. Cornely OA, et al. Clin Infect Dis. 2012;55(suppl 2):s154-s161. 5. Leong C, Zelenitsky S. Can J Hosp Pharm. 2013;66(6):361-368. 6. Kelly CP. Clin Microbiol Infect. 2012;18(suppl 6):21-27. 7. Riddle DJ, et al. Infect Dis Clin North Am. 2009;23(3):727-743. 8. Smits WK, et al. Nat Rev Dis Primers. 2016;2:16020. 9. Nelson WW, et al. J Manag Care Spec Pharm. 2021;27(7):828-838. 10. Feuerstadt P, et al. SAGE Open Med. 2021;9:2050312120986733. 11. Sandhu A, et al. Emerg Infect Dis. 2020;26(9):2272-2274. 12. Rodrigues R, et al. Infect Control Hosp Epidemiol. 2017;38(2):196-202. 13. McDonald LC, et al. Clin Infect Dis. 2018;66(7):e1-e48. 14. Zilberberg MD, et al. Medicine. 2018;97(36):e12212. doi:10.1097/MD.0000000000012212. 15. Lurienne L, et al. J Patient Rep Outcomes. 2020;4(1):14.